Story · Medicine & Biotech

GLP-1 Antagonist Shows Clinically Meaningful Results in Post-Bariatric Hypoglycemia

2 outlets · first reported by Healio on · latest · 23 hours of coverage

(MedPage Today) -- NATIONAL HARBOR, Md. -- An investigational first-in-class GLP-1 receptor antagonist significantly reduced hypoglycemic events after bariatric surgery in the phase III LUCIDITY trial. From a baseline mean of 2.39 events per... (MedPage Today)

Coverage, in order

  1. first Healio indie randomized trial
    GLP-1 receptor antagonist reduces post-bariatric hypoglycemia

    NATIONAL HARBOR, Md. — A GLP-1 receptor antagonist reduced occurrences of level 2 and level 3 hypoglycemia for adults diagnosed with post-bariatric hypoglycemia, according to data from the phase 3 LUCIDITY trial. Marilyn Tan, MD, FACE, FACP, clinical professor of medicine (endocrinology) at…

  2. MedPage Today indie randomized trial
    GLP-1 Antagonist Shows Clinically Meaningful Results in Post-Bariatric Hypoglycemia

    (MedPage Today) -- NATIONAL HARBOR, Md. -- An investigational first-in-class GLP-1 receptor antagonist significantly reduced hypoglycemic events after bariatric surgery in the phase III LUCIDITY trial. From a baseline mean of 2.39 events per...

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.